RU2009149359A - Состав вакцин против менингита - Google Patents
Состав вакцин против менингита Download PDFInfo
- Publication number
- RU2009149359A RU2009149359A RU2009149359/15A RU2009149359A RU2009149359A RU 2009149359 A RU2009149359 A RU 2009149359A RU 2009149359/15 A RU2009149359/15 A RU 2009149359/15A RU 2009149359 A RU2009149359 A RU 2009149359A RU 2009149359 A RU2009149359 A RU 2009149359A
- Authority
- RU
- Russia
- Prior art keywords
- conjugate
- water
- saccharide
- influenzae
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 25
- 201000009906 Meningitis Diseases 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 45
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract 28
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract 28
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract 15
- 239000002671 adjuvant Substances 0.000 claims abstract 14
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims abstract 9
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 9
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims abstract 8
- 239000012528 membrane Substances 0.000 claims abstract 6
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract 4
- 229940001442 combination vaccine Drugs 0.000 claims abstract 4
- 239000007762 w/o emulsion Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 229960003983 diphtheria toxoid Drugs 0.000 claims 9
- 230000000844 anti-bacterial effect Effects 0.000 claims 7
- 241000991587 Enterovirus C Species 0.000 claims 6
- 241000700721 Hepatitis B virus Species 0.000 claims 6
- 201000005702 Pertussis Diseases 0.000 claims 6
- 230000005875 antibody response Effects 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 3
- 230000004044 response Effects 0.000 claims 2
- 239000002569 water oil cream Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93323507P | 2007-06-04 | 2007-06-04 | |
| US60/933,235 | 2007-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009149359A true RU2009149359A (ru) | 2011-07-20 |
Family
ID=40094241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009149359/15A RU2009149359A (ru) | 2007-06-04 | 2008-06-04 | Состав вакцин против менингита |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100203137A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2152302B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5637848B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101678094B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2008259423A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0811979A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2688268A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2555786T3 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2009KN04098A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009013112A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ581367A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2009149359A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008149238A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX343752B (es) | 1998-05-01 | 2016-11-22 | Novartis Vaccines & Diagnostics Inc | Antigenos de neisseria meningitidis y composiciones que los contienen. |
| WO2000071725A2 (en) | 1999-05-19 | 2000-11-30 | Chiron S.P.A. | Combination neisserial compositions |
| PT2275551E (pt) | 1999-10-29 | 2015-06-29 | Novartis Vaccines & Diagnostic | Péptidos antigénicos de neisseria |
| ATE503837T1 (de) | 2000-02-28 | 2011-04-15 | Novartis Vaccines & Diagnostic | Hybride expression neisserscher proteine |
| WO2002000249A2 (en) * | 2000-06-29 | 2002-01-03 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine composition |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| DK2283857T3 (da) | 2005-06-27 | 2019-10-28 | Glaxosmithkline Biologicals Sa | Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| ATE553774T1 (de) * | 2007-10-19 | 2012-05-15 | Novartis Ag | Meningokokkenimpfstoffformulierungen |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| AU2009268937A1 (en) * | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| RU2555757C2 (ru) * | 2009-03-24 | 2015-07-10 | Новартис Аг | Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов |
| HRP20201076T1 (hr) * | 2009-03-24 | 2020-10-30 | Glaxosmithkline Biologicals Sa | Adjuvantni vezujući protein meningokokalnog faktora h |
| US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
| FI2608805T4 (fi) | 2010-08-23 | 2025-08-07 | Wyeth Llc | NEISSERIA MENINGITIDIS rLP2086 -ANTIGEENIEN STABIILEJA FORMULAATIOITA |
| CA2809758C (en) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| RU2013131795A (ru) * | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
| IN2012MU00206A (cg-RX-API-DMAC7.html) * | 2012-01-20 | 2013-08-09 | ||
| CN104159602B (zh) * | 2012-03-08 | 2017-10-24 | 葛兰素史密丝克莱恩生物有限公司 | 加强疫苗的含佐剂制剂 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX351993B (es) | 2012-03-09 | 2017-11-03 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| CN104602704B (zh) | 2012-06-14 | 2019-08-06 | 诺华股份有限公司 | 针对血清组x脑膜炎球菌的疫苗 |
| ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
| MX380129B (es) | 2013-09-08 | 2025-03-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos |
| CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
| WO2018045286A1 (en) | 2016-09-02 | 2018-03-08 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
| IL267733B2 (en) | 2017-01-31 | 2023-10-01 | Pfizer | Neisseria meningitidis compositions and methods thereof |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| ES2171418T3 (es) | 1992-08-31 | 2002-09-16 | Baxter Healthcare Sa | Vacunas contra neisseria meningitidis del grupo c. |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| EA199700413A1 (ru) | 1995-06-23 | 1998-08-27 | Смитклайн Бичам Байолоджикалз, С.А. | Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| WO2002000249A2 (en) | 2000-06-29 | 2002-01-03 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine composition |
| EP2332581B1 (en) | 2001-01-23 | 2015-07-01 | Sanofi Pasteur Inc. | Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| WO2003080678A1 (en) | 2002-03-26 | 2003-10-02 | Chiron Srl | Modified saccharides having improved stability in water |
| CN102302776B (zh) * | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
| CN103405761A (zh) | 2003-10-02 | 2013-11-27 | 诺华疫苗和诊断有限公司 | 多种脑膜炎球菌血清群的液体疫苗 |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN1709505B (zh) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
| CA2621023C (en) * | 2005-09-01 | 2019-07-02 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Multiple vaccination including serogroup c meningococcus |
| GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| ATE553774T1 (de) * | 2007-10-19 | 2012-05-15 | Novartis Ag | Meningokokkenimpfstoffformulierungen |
-
2008
- 2008-06-04 ES ES08789070.3T patent/ES2555786T3/es active Active
- 2008-06-04 RU RU2009149359/15A patent/RU2009149359A/ru not_active Application Discontinuation
- 2008-06-04 MX MX2009013112A patent/MX2009013112A/es active IP Right Grant
- 2008-06-04 AU AU2008259423A patent/AU2008259423A1/en not_active Abandoned
- 2008-06-04 IN IN4098KON2009 patent/IN2009KN04098A/en unknown
- 2008-06-04 CN CN200880018507.2A patent/CN101678094B/zh not_active Expired - Fee Related
- 2008-06-04 WO PCT/IB2008/002121 patent/WO2008149238A2/en not_active Ceased
- 2008-06-04 EP EP08789070.3A patent/EP2152302B1/en active Active
- 2008-06-04 BR BRPI0811979-1A2A patent/BRPI0811979A2/pt not_active IP Right Cessation
- 2008-06-04 NZ NZ581367A patent/NZ581367A/en not_active IP Right Cessation
- 2008-06-04 CA CA2688268A patent/CA2688268A1/en not_active Abandoned
- 2008-06-04 JP JP2010510910A patent/JP5637848B2/ja not_active Expired - Fee Related
- 2008-06-04 US US12/451,831 patent/US20100203137A1/en not_active Abandoned
-
2014
- 2014-07-15 AU AU2014204425A patent/AU2014204425B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008149238A3 (en) | 2009-08-06 |
| JP2010529103A (ja) | 2010-08-26 |
| CN101678094A (zh) | 2010-03-24 |
| JP5637848B2 (ja) | 2014-12-10 |
| AU2008259423A1 (en) | 2008-12-11 |
| BRPI0811979A2 (pt) | 2014-10-21 |
| AU2014204425B2 (en) | 2015-10-29 |
| MX2009013112A (es) | 2010-03-01 |
| WO2008149238A2 (en) | 2008-12-11 |
| NZ581367A (en) | 2012-05-25 |
| EP2152302A2 (en) | 2010-02-17 |
| CN101678094B (zh) | 2014-08-27 |
| US20100203137A1 (en) | 2010-08-12 |
| CA2688268A1 (en) | 2008-12-11 |
| EP2152302B1 (en) | 2015-10-07 |
| IN2009KN04098A (cg-RX-API-DMAC7.html) | 2015-08-28 |
| ES2555786T3 (es) | 2016-01-08 |
| AU2014204425A1 (en) | 2014-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009149359A (ru) | Состав вакцин против менингита | |
| US11135279B2 (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| RU2006142156A (ru) | Объединенные менингококковые конъюгаты с общим белком-носителем | |
| RU2009134033A (ru) | Жидкие вакцины для множественных серогрупп менингококков | |
| JP5346308B2 (ja) | ワクチン組成物 | |
| RU2008112289A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
| JP2004501873A5 (cg-RX-API-DMAC7.html) | ||
| RU2009108660A (ru) | Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов | |
| RU2004136299A (ru) | Мукозальные вакцины с хитозановым адъювантом и/или антигенами менингококков | |
| JP2014506916A5 (cg-RX-API-DMAC7.html) | ||
| RU2007130774A (ru) | Вакцинация менингококковыми конъюгатами | |
| CZ418997A3 (cs) | Kombinovaná vakcína, souprava, která ji obsahuje a způsob výroby této vakcíny | |
| JP2014218516A5 (cg-RX-API-DMAC7.html) | ||
| JP2018115159A (ja) | 肺炎球菌ワクチンにおいて用いるための免疫原性組成物 | |
| RU2011142774A (ru) | Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов | |
| CN105267974A (zh) | 用于缀合疫苗的经过修饰的多糖 | |
| RU2010119947A (ru) | Составы менингококковых вакцин | |
| AU5017093A (en) | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines | |
| RU2006142158A (ru) | Вакцинация менингококковыми конъюгатами | |
| JP2006528936A5 (cg-RX-API-DMAC7.html) | ||
| RU2007138492A (ru) | Комбинированные вакцины с антигеном коклюша цельных клеток | |
| PL174130B1 (pl) | Złożona szczepionka pediatryczna przeciwko błonicy, tężcowi, ksztuścowi oraz Haemophilus influenzae typu b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130826 |